Anticholinergic Deprescription in Schizophrenia
NCT06562608
This study is recruiting at 1 US site in 1 state, according to its ClinicalTrials.gov record last updated .
Summary
In this study, the investigators will examine whether a deprescription of unnecessary anticholinergic drugs (benztropine or trihexyphenidyl) can augment quality of life, functioning, and neurocognition in individuals who with schizophrenia. Individuals identified by clinical services who have unneeded prescriptions benztropine or trihexyphenidyl will be eligible for deprescription and study entry.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Schizophrenia
- Schizoaffective Disorder
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 4
- Ages
- 40 to 70 years
- Sex
- All
- Healthy volunteers
- Accepted
- Sponsor
- Deepak K. Sarpal, M.D.
- Last updated on ClinicalTrials.gov
- July 10, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Pennsylvania · 1
- UPMC Western Psychiatric Hospital/University of Pittsburgh · Pittsburgh, PA
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.